Exoxemis

Executive Summary

Exoxemis is a private biopharmaceutical company focused on drug delivery, with its lead candidate Zempia aimed at treating open wounds. The company has completed a pivotal, placebo-controlled, randomized Phase III trial enrolling 250 subjects per arm across 25 U.S. and 5 Israeli sites. The study demonstrated that Zempia is safe for use in open wounds and does not interfere with normal wound healing, providing a strong foundation for regulatory submission. Exoxemis is positioned to address a significant unmet need in wound care, though detailed efficacy data and financial backing remain to be fully disclosed.

Upcoming Catalysts (preview)

• Q1 2027FDA submission for Zempia65% success
• Q3 2026Publication of Phase III results in peer-reviewed journal85% success
• Q2 2026Strategic partnership or licensing deal40% success